The present invention relates to a compound of formula (I)

##STR00001## wherein A, Z, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors of TEAD. The compounds are useful as medicaments in the treatment of diseases or conditions wherein inhibition of TEAD is desired, such as cancer and chronic pain.

The present invention relates to a compound of formula (I)

##STR00001## wherein A, Z, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors of TEAD. The compounds are useful as medicaments in the treatment of diseases or conditions wherein inhibition of TEAD is desired, such as cancer and chronic pain.

The present invention relates to the field of polymerisation catalysts, and systems comprising these catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I):

##STR00001##

wherein at least one of M.sub.1 or M.sub.2 is selected from Ni(II) and Ni(III)-X. A process for the reaction of carbon dioxide with an epoxide; an epoxide and an anhydride; and/or a lactide and/or a lactone in the presence of the catalyst is also described.

The present invention relates to the field of polymerisation catalysts, and systems comprising these catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I):

##STR00001##

wherein at least one of M.sub.1 or M.sub.2 is selected from Ni(II) and Ni(III)-X. A process for the reaction of carbon dioxide with an epoxide; an epoxide and an anhydride; and/or a lactide and/or a lactone in the presence of the catalyst is also described.

The disclosure provides for compounds having immunoproteasome inhibitory activity, and pharmaceutical compositions made thereof. The disclosure further provides for the use of the compounds and compositions in treating various diseases and disorders in a subject that are associated with immunoproteasome activity, including inflammatory disorders, autoimmune disorders, hematological disorders, and neurodegenerative disorders.

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression.

A subject of the present invention is the use of a compound having the general formula (I): (I) wherein V, W, X.sub.4, X.sub.5, X.sub.6, X.sub.7, X.sub.4, X.sub.5, X.sub.6, X.sub.7, Y, Y, R.sub.3, R.sub.3, R.sub.4 and R.sub.4 are as defined in any one of claims 1 to 11, for the detection, capture and/or separation of polluting gases, in particular those selected from the group comprising carbon dioxide, methane, sulfur dioxide, nitrogen oxides, carbon monoxide, linear hydrocarbons, linear mono-olefins and their mixtures, and preferably carbon dioxide. Another subject of the invention is a compound of formula (I) wherein V, W, X.sub.4, X.sub.5, X.sub.6, X.sub.7, X.sub.4, X.sub.5, X.sub.6, X.sub.7, Y, Y, R.sub.3, R.sub.3, R.sub.4 and R.sub.4 are as defined in any one of claims 12 to 21.

##STR00001##

A subject of the present invention is the use of a compound having the general formula (I): (I) wherein V, W, X.sub.4, X.sub.5, X.sub.6, X.sub.7, X.sub.4, X.sub.5, X.sub.6, X.sub.7, Y, Y, R.sub.3, R.sub.3, R.sub.4 and R.sub.4 are as defined in any one of claims 1 to 11, for the detection, capture and/or separation of polluting gases, in particular those selected from the group comprising carbon dioxide, methane, sulfur dioxide, nitrogen oxides, carbon monoxide, linear hydrocarbons, linear mono-olefins and their mixtures, and preferably carbon dioxide. Another subject of the invention is a compound of formula (I) wherein V, W, X.sub.4, X.sub.5, X.sub.6, X.sub.7, X.sub.4, X.sub.5, X.sub.6, X.sub.7, Y, Y, R.sub.3, R.sub.3, R.sub.4 and R.sub.4 are as defined in any one of claims 12 to 21.

##STR00001##

The present invention relates to the field of polymerisation catalysts, and systems comprising these catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I): ##STR00001##
wherein at least one of M.sub.1 or M.sub.2 is selected from Ni(II) and Ni(III)-X. A process for the reaction of carbon dioxide with an epoxide; an epoxide and an anhydride; and/or a lactide and/or a lactone in the presence of the catalyst is also described.

Compounds that regulate quorum sensing in Staphylococcal bacteria and in particular in Staphylococcus aureus are provided. Compounds are described in formulas I, II, III, IV, V and VI herein. One or more compounds herein can be employed to inhibit QS and to thus inhibit virulence in Staphylococcus bacteria and in particular in Staphylococcus aureus. Compounds herein and pharmaceutical compositions containing one or more of these compounds are useful, for example, in treating infections of Staphylococcus bacteria and in particular of Staphylococcus aureus. Methods for treating such bacterial infections are provided.